Redmile Group, LLC reported 37 positions worth $1.45B for the quarter ended Jun 30, 2026, down 3.6% on the prior quarter. It opened 4 new positions, added to 4, trimmed 22 and exited 0. Its largest holding is Scholar Rock Holding Corp at 16.4% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| CLYM Climb Bio, Inc. | +1.23M | $15.99M | 1.1% |
| AURA Aura Biosciences, Inc. | +1.67M | $11.83M | 0.816% |
| STTK Shattuck Labs, Inc. | +1.35M +24.4% | $9.39M | 3.3% |
| ODTX Odyssey Therapeutics, Inc. | +425.0K | $7.95M | 0.548% |
| CLDX Celldex Therapeutics, Inc. | +172.4K +65.9% | $6.42M | 1.11% |
| INSM INSMED Inc | +51.2K | $5.46M | 0.377% |
| BMRN Biomarin Pharmaceutical Inc | +91.3K +52.5% | $5.22M | 1.05% |
| IDYA IDEAYA Biosciences, Inc. | +119.1K +22.9% | $4.44M | 1.65% |
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| SRRK Scholar Rock Holding Corp | -4.76M -52.5% | $261.55M | 16.35% |
| NRIX Nurix Therapeutics, Inc. | -3.66M -47.3% | $88.77M | 6.82% |
| ABSI Absci Corp | -1.51M -18.3% | $17.54M | 5.39% |
| KRYS Krystal Biotech, Inc. | -41.5K -6.2% | $15.42M | 16.2% |
| ANNX Annexon, Inc. | -2.68M -18.4% | $15.30M | 4.67% |
| IMNM Immunome Inc. | -647.3K -11.6% | $13.72M | 7.18% |
| COGT Cogent Biosciences, Inc. | -184.7K -26.8% | $7.15M | 1.34% |
| STOK Stoke Therapeutics, Inc. | -218.2K -5.2% | $7.14M | 8.9% |
| ADCT ADC Therapeutics SA | -3.94M -25.5% | $4.22M | 0.851% |
| BEAM Beam Therapeutics Inc. | -73.4K -5.9% | $2.52M | 2.76% |
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | SRRK Scholar Rock Holding Corp | Healthcare | 4.31M | $237.11M | 16.35% | -4.76M | -52.5% | Reduced | 3.3% |
| 2 | KRYS Krystal Biotech, Inc. | Healthcare | 632.0K | $234.90M | 16.2% | -41.5K | -6.2% | Reduced | 2.14% |
| 3 | STOK Stoke Therapeutics, Inc. | Healthcare | 3.95M | $129.11M | 8.9% | -218.2K | -5.2% | Reduced | 5.98% |
| 4 | IMNM Immunome Inc. | Healthcare | 4.91M | $104.08M | 7.18% | -647.3K | -11.6% | Reduced | 4.33% |
| 5 | NRIX Nurix Therapeutics, Inc. | Healthcare | 4.07M | $98.83M | 6.82% | -3.66M | -47.3% | Reduced | 3.67% |
| 6 | ABSI Absci Corp | Healthcare | 6.74M | $78.11M | 5.39% | -1.51M | -18.3% | Reduced | 3.93% |
| 7 | ANNX Annexon, Inc. | Healthcare | 11.87M | $67.78M | 4.67% | -2.68M | -18.4% | Reduced | 5.91% |
| 8 | RGNX REGENXBIO Inc. | Healthcare | 4.37M | $52.34M | 3.61% | 0 | 0.0% | Unchanged | 8.07% |
| 9 | STTK Shattuck Labs, Inc. | Healthcare | 6.89M | $47.83M | 3.3% | +1.35M | +24.4% | Added | 5.31% |
| 10 | NGNE Neurogene Inc. | Healthcare | 1.41M | $44.41M | 3.06% | -47.4K | -3.2% | Reduced | 6.26% |
| 11 | BEAM Beam Therapeutics Inc. | Healthcare | 1.16M | $39.96M | 2.76% | -73.4K | -5.9% | Reduced | 1.12% |
| 12 | FATE Fate Therapeutics Inc | Healthcare | 12.87M | $34.76M | 2.4% | 0 | 0.0% | Unchanged | 10.69% |
| 13 | IDYA IDEAYA Biosciences, Inc. | Healthcare | 640.2K | $23.86M | 1.65% | +119.1K | +22.9% | Added | 0.66% |
| 14 | SLN Silence Therapeutics plc | Healthcare | 2.16M | $23.77M | 1.64% | 0 | 0.0% | Unchanged | 4.58% |
| 15 | COGT Cogent Biosciences, Inc. | Healthcare | 503.3K | $19.48M | 1.34% | -184.7K | -26.8% | Reduced | 0.29% |
Tip. Select a row to see that position’s full history at Redmile.
As of its Q2 2026 13F filing, Redmile Group, LLC’s five largest positions were Scholar Rock Holding Corp (SRRK) at 16.4%, Krystal Biotech, Inc. (KRYS) at 16.2%, Stoke Therapeutics, Inc. (STOK) at 8.9%, Immunome Inc. (IMNM) at 7.2%, Nurix Therapeutics, Inc. (NRIX) at 6.8% of the reported portfolio.
Redmile Group, LLC reported a 13F portfolio worth $1.45B across 37 positions for Q2 2026. That is down 3.6% from the previous quarter.
Its largest purchases by value were Climb Bio, Inc. ($15.99M), Aura Biosciences, Inc. ($11.83M), Shattuck Labs, Inc. ($9.39M). It opened 4 new positions.
Its largest sales by value were Scholar Rock Holding Corp ($261.55M), Nurix Therapeutics, Inc. ($88.77M), Absci Corp ($17.54M). It exited 0 positions entirely.
From the Form 13F-HR reports Redmile Group, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.